Belimumab Biosimilar - Research Grade

McElroy, W. & Heger, CD. Development of the SupersonicIEF Method for High-Throughput Charge Variant Analysis. Electrophoresis, 2024 45, 21-22, 1968-1975.

Human

BAFF

>1mg/ml

Human IgG1 E239D, M241L-Human lambda3 K83R

Tabalumab Biosimilar - Research Grade (ICH5103)

https://www.imgt.org/mAb-DB/

ICH3002

Q9Y275

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of belimumab, a fully human IgG1-lambda antibody directed against soluble human BAFF (B-cell activating factor, also called BLyS/TNFSF13B). It is supplied for research use only and is not the clinical drug; it is not intended for human or veterinary use. Built around the BAFF target, it is useful as a well-defined binding and neutralization reagent for interrogating the BAFF-BAFF receptor axis in vitro. Typical research applications include positive/reference controls in ligand-binding and blocking assays, characterization of BAFF-dependent B-cell survival signaling, benchmarking of novel anti-BAFF binders, epitope and affinity comparisons, and as a tool antibody in preclinical assay development including ADCC/ADC and reporter-based formats. The material is produced at research grade with low endotoxin (typically <1 EU/mg, with an ultra-low <0.5 EU/mg option) and is available in bulk milligram-to-gram quantities to support screening, standardization, and scale-up workflows without therapeutic-grade cost or regulatory constraints. BAFF (B-cell activating factor; also known as BLyS, TALL-1, TNFSF13B; UniProt Q9Y275) is a type II transmembrane member of the TNF superfamily expressed by myeloid cells, dendritic cells, and stromal cells. It is cleaved from the membrane to a soluble form that assembles into trimers (and higher-order 60-mer structures) and signals through three receptors on B cells: BAFF-R (TNFRSF13C), TACI (TNFRSF13B), and BCMA (TNFRSF17). BAFF is a key survival and maturation factor for transitional and mature B cells, promoting peripheral B-cell homeostasis, and it also supports plasma cell survival and immunoglobulin class switching. A related ligand, APRIL, shares TACI and BCMA. Excess BAFF drives survival of autoreactive B cells and is implicated in systemic lupus erythematosus and other autoimmune disease, which is the rationale for therapeutic BAFF neutralization.

TNFSF13B

Detects human TNFSF13B. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Belimumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Belimumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Belimumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Belimumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Belimumab that binds human BAFF.